Announcements Trials
Browse Landscape

Status

Completed 2Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Observational 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Neoplasms 3216Carcinoma, Non-Small-Cell Lung 2729Breast Neoplasms 2551Colorectal Neoplasms 1463Prostatic Neoplasms 1307Neoplasm Metastasis 1301Multiple Myeloma 1112Melanoma 1103Ovarian Neoplasms 1006Lung Neoplasms 945Recurrence 924Leukemia, Myeloid, Acute 879Pancreatic Neoplasms 833Lymphoma, Non-Hodgkin 767Lymphoma 713Stomach Neoplasms 692Carcinoma, Renal Cell 660Carcinoma, Hepatocellular 647Leukemia, Lymphocytic, Chronic, B-Cell 560Squamous Cell Carcinoma of Head and Neck 550Lymphoma, Follicular 515Head and Neck Neoplasms 490Glioblastoma 473Small Cell Lung Carcinoma 447Lymphoma, Large B-Cell, Diffuse 440Triple Negative Breast Neoplasms 436Advanced Solid Tumors 432Leukemia 426Uterine Cervical Neoplasms 420Urinary Bladder Neoplasms 405

Interventions

darolutamide 4enzalutamide 2apalutamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Non-metastatic Castration-resistant Prostate Cancer × Clear all
NCT07538843 2026-05-15

DARE

Bayer

Not yet recruiting
800 enrolled
Genitourinary

Non-metastatic Castration-resistant Prostate Cancer

NCT06334120 2026-05-13

An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea

Bayer

Recruiting
600 enrolled
Genitourinary

Non-metastatic Castration-resistant Prostate Cancer

NCT06013475 2025-06-12

DEAR-EXT

Bayer

Completed
1,375 enrolled
Genitourinary

Non-metastatic Castration-resistant Prostate Cancer

NCT05362149 2024-03-20

DEAR

Bayer

Completed
870 enrolled
Genitourinary

Non-metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡